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Abstract
Major surgical resection is often the only curative treatment for cholangiocarcinoma. When imaging techniques fail to
establish the accurate diagnosis, biopsy of the lesion is unavoidable. However, biopsy is not necessarily required for
topography of the cholangiocarcinoma (intrahepatic or extrahepatic). 1) In extrahepatic cholangiocarcinoma (ECC),
clinical features and radiological imaging relate to biliary obstruction. Provided that between 8% and 43% of bile duct
strictures are not ECC, the lesions mimicking ECC that should be ruled out are gallbladder cancer, Mirizzi syndrome,
primary sclerosing cholangitis (PSC), autoimmune pancreatitis and portal biliopathy. Systematic biopsy is usually difficult
and has poor sensitivity, but a good knowledge of these mimicking ECC diseases, along with precise analysis of clinical and
imaging semiology, may lead to a correct diagnosis without the need for biopsy. 2) Intrahepatic cholangiocarcinoma (ICC)
developing in normal liver appears as a hypovascular tumour with fibrotic component and capsular retraction that can be
confused with fibrous metastases such as breast and colorectal cancers. The lack of the primary site, a relatively large
tumour size and ancillary findings such as bile duct dilatation may provide a clue to the diagnosis. If not, we advocate local
resection with lymph node dissection, since ICC is the most likely diagnostis and surgery is the only curative treatment. In
the event of adenocarcinoma from unknown primary, surgery is an effective treatment even if prognosis is poor.
Introduction
Radical resection is the only curative treatment of
cholangiocarcinoma occurring at any level of the biliary
tract, i.e. within the liver (intrahepatic cholangiocarci-
noma; ICC) or from extrahepatic bile ducts (extra-
hepatic cholangiocarcinoma; ECC). Preoperative
biopsy of the lesion seems unavoidable when major
surgery is planned, which is necessary in most cases.
However, systematic biopsy is often difficult in
patients with ECC, but we believe that a good
knowledge of diseases mimicking cholangiocarcinoma
combined with precise patient semiologic analysis
may lead to a correct diagnosis without the need for
biopsy. In our experience, and in accordance with a
review of the literature, the aim of this article was to
describe a preoperative strategy in patients suspected
of cholangiocarcinoma.
Extrahepatic cholangiocarcinoma
ECC is generally an infiltrative and sclerosing adeno-
carcinoma leading to biliary obstruction. It affects
men more often than it affects women, and in the age
range 50 to 70 years. Clinical presentation of ECC is
related to biliary obstruction, i.e. jaundice, dark urine,
pale stool and pruritus [1,2]. Biochemical examina-
tion shows high levels of serum bilirubin, alcalin
phosphatases and gamma glutamyl transpeptidase.
Cancer Antigen 19-9 (CA19-9) is often elevated but
without lack of specificity. Radiological examinations
are essential for diagnosis and staging before treat-
ment of ECC [3]. CT scan, which reveals intrahepatic
bile duct dilatation up to the site of obstruction,
assesses vessel encasement, often associated liver
atrophy and detects lymphadenopathy. Magnetic
resonance cholangiopancreatography (MRCP) refines
these findings and allows cholangiography without the
risk of cholangitis or pancreatitis. It shows localized
strictures, often irregular, bile duct above and below
the obstruction, vessel encasement, invasion of adja-
cent liver parenchyma by hilar cholangiocarcinomas,
local lymphadenopathy and distant metastases. How-
ever, as indicated in Table I, between 8% and 43% of
biliary strictures are not ECC, including malignant
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strictures other than ECC and benign strictures [4
14]. These non-ECC biliary strictures must be
researched before patients are referred to long and
risky surgical treatment of ECC.
There are several arguments in favour of preopera-
tive biopsy, especially when imaging techniques fail to
demonstrate a mass lesion [3]. Additionally, surgery
can be performed in suitable candidates, and with
greater confidence, when there is a positive tissue
diagnosis. However, a percutaneous approach with
ultrasonography (US) or computed tomography (CT)
guidance may fail because of the absence of a visible
mass. This approach has also been considered inad-
visable because of the possible risk of intra-abdominal
seeding of tumour cells [15]. It has therefore been
proposed that direct methods tissue sampling  either
via the biliary duct during endoscopic retrograde
cholangiopancreatography (ERCP) or percutaneous
cholangiography (PTC), or by a trans-duodenal or
trans-gastric route with endoscopic ultrasound (EUS)
guidance  may yield better results, with a potentially
lower risk of tumour cell spread. Ideally, any tissue
sampling technique used should be highly sensitive in
detecting cancer, and with absolute specificity. The
technique should be simple, safe and relatively
inexpensive for widespread used. Unfortunately,
none of the currently used tissue sampling methods
have all these characteristics. All current methods
have relatively low to moderate sensitivity but almost
100% specificity [16].
The main tissue sampling methods during endo-
scopic procedures are ERCP brush cytology, forceps
biopsy and fine-needle aspiration (FNA) and EUS-
guided FNA [16]. Brushing is the most frequently
used tissue sampling technique because it is techni-
cally easy, requires little time and is generally safe.
Although it has specificity close to 100%, brush
cytology is less sensitive in detecting cancer, ranging
from 18% to 60% in most published series [1726]. It
has been suggested that this limited sensitivity is at
least partially due to failure to obtain an adequate
cellular yield. This may be attributed to submucosal
tumour growth or to extrinsic location of the tumour
with compression of the biliary tree [22,27]. Some
authors have found that the cancer detection rate of
bile cytology increases from 27% to 63% with
stricture dilatation [28], and even more using a
scraping brush [29]. Finally, two consecutives brush-
ings increase the cancer detection rate from 33% (one
brushing) to 44% [30]. The endobiliary forceps
biopsy provides a sample of bile duct tissue deep to
the epithelium, theoretically obviating the problem of
inadequate sampling that may occur with brushing.
This technique is more time-consuming than brush-
ing and is less widely used [16]. Sensibility of the
technique rises from 43% to 81%, with specificity of
around 100% [20,24,25]. Several studies have shown
that combining several techniques for obtaining tissue
samples from biliary strictures at ERCP enhances the
detection of cancer. When combining brushing,
biopsy and endoscopic FNA, sensibility reaches 70%
[20,31,32].
In a recent systematic survey of prospective studies
including 16,855 patients, the rate of ERCP-attribu-
table complications was 7%, including pancreatitis
(3.5%), sepsis (1.4%), bleeding (1.3%) and perfora-
tions (0.6%) [33]. Complications directly related to
brushing are very rare. One retroperitoneal perfora-
tion was reported in a series of 223 consecutive
brushings [24], with the rate of post-procedure
pancreatitis B2% [34]. Complications relating to
the use of forceps are uncommon. Minor bleedings
have been reported [24].
There are few published data with respect to EUS-
FNA of biliary tumours. Recent studies have obtained
excellent results, i.e. with 86% to 89% sensitivity
[35,36]. In one prospective study comparing ERCP
and EUS in the diagnosis of biliary strictures, it was
concluded that ERCP-based tissue acquisition may be
better for biliary tumours, whereas EUS-FNA is
preferable for pancreatic mass lesions [37].
Finally, we did not find any cost effectiveness study
in the literature about preoperative tissue sampling for
cholangiocarcinoma. Thus, other aetiologies of biliary
strictures which may mimic ECC must be considered
before referring the patient for surgical resection. We
advocate that good knowledge of the literature and
precise semiologic analysis may lead to the true
diagnosis without biopsy.
Table I. Studies dealing with biliary strictures mimicking ECC.
n ECC Non-ECC (%) Gallbladder cancer Lithiasis PSC SSC Others (malign)
Hadjis 1985 [8] 104 96 8 (17) 8
Wetter 1991 [13] 98 68 30 (31) 12 2 6 10
Verbeek 1992 [12] 82 71 11 (13) 11
Nakayama 1999 [10] 99 85 14 (14) 14
Gerhards 2001 [7] 132 112 20 (15) 3 17
Knoefel 2003 [14] 33 27 6 (18) 6
Koea 2004 [9] 49 28 21 (43) 7 2 10 2
Corvera 2005 [6] 275 253 22 (8) 6 3 13
Are 2006 [4] 171 141 30 (18) 16 1 8 5
ECC: extrahepatic cholangiocarcinoma; PSC: primary sclerosing cholangitis; SSC: secondary sclerosing cholangitis.
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Malign aetiologies mimicking ECC
1) Carcinoma of the gallbladder.  Although the main
location of stricture is usually below the biliary
confluence, this diagnosis must be considered system-
atically. Indeed, it is the most common cause of
malignant bile duct stricture in the mid-portion of the
common duct. The mechanism can be either invasion
or compression. On imaging, diagnosis can be sus-
pected on: (a) presence of an enlarged gallbladder
with gallstones, (b) localized gallbladder wall thicken-
ing, or (c) invasion of the liver. Occlusion of the cystic
duct at endoscopic cholangiography suggests gallblad-
der carcinoma [38]. Anomaly of a pancreaticobiliary
duct junction is associated with gallbladder carcinoma
in about one-fifth, and must be investigated [39].
Finally, patients with carcinoma of gallbladder pre-
senting with jaundice are at particularly high risk of
portal vein invasion with poor prognosis because this
is not amenable to surgery [40].
2) Lymph node metastases.  Lymph node metastases
in the porta hepatis can also cause extrahepatic biliary
tree compression. Main causes of lymph node metas-
tasis include colorectal metastases, carcinoma of the
breast, lung, stomach, kidney, malignant melanoma
and lymphoid neoplasm [4143]. Clinical features
and imaging can usually make the difference from
ECC. Treatment is endoscopic and/or aetiologic.
Benign aetiologies mimicking ECC
Between 8% and 28% of bile duct strictures are of
benign origin [413]. According to the literature, the
following aetiologies are the most frequent.
1) Mirizzi syndrome.  Mirizzi syndrome is defined
as a common hepatic duct obstruction caused by an
impacted stone in the gallbladder neck or cystic duct.
Although its incidence is very low, at about 0.72.5%
[38,44,45], this diagnosis requires US and magnetic
resonance imaging (MRI) to reveal the presence of a
large stone. Local inflammatory reaction at the site of
stone intrusion can be diagnosed by CT. ERCP, PTC
and especially MRCP can show the extrinsic narrow-
ing that bows the main bile duct to the left, with a
stricture usually long and smooth (Figure 1) [4648].
2) Primary sclerosing cholangitis (PSC) (Figure 2). 
This autoimmune disorder affects periductal tissues of
the biliary tree, leading to multifocal strictures of
intrahepatic and extrahepatic bile duct. It is associated
with ulcerative rectocolitis in up to 75% of cases. This
pre-cancerous lesion can degenerate in 8% of cases
[49]. Management of a patient with PSC and
suspected CC is difficult. In a patient with PSC,
there are roughly two difficult situations. The first is
the presence of localized bile duct stricture mimicking
CC. In this setting, the patient should be extensively
explored for indications in favour of PSC, including:
(a) long-standing non-icteric cholestasis; (b) presence
of ulcerative colitis; (c) radiologic features in intrahe-
patic bile ducts of distant strictures; and (d) liver
biopsy showing aspects of PSC [50]. The second
difficult situation is a high suspicion of CC in a patient
with PSC, because cholangiocarcinoma in the setting
of PSC is of poor prognosis, and usually contra-
indicates liver transplantation (LT). The presence of
ECC should be highly suspected when the patient has
had major changes in clinical symptoms, including
during onset of the disease. However, results of LT in
selected patients with PSC associated with early CC
can be favourable providing the tumour is not
associated with lymph node involvement and also
providing the transplant procedure is initiated by
radio-chemotherapy [51]. CA19-9 is useful in this
case. A value 100 U/ml has great sensibility and
specificity for the diagnosis of malignant transforma-
tion [52,53]. In this situation, histological or cytolo-
gical examination of the stricture by means of biopsy
or brush cytology is required [54].
3) Secondary sclerosing cholangitis (SSC).  SSC is a
disease that is morphologically similar to PSC but
differs in pathological process. Among several infec-
tions that can lead to SSC and mimic ECC are:
Figure 1. MRCP of mirizzi syndrome.
Figure 2. MRCP of primary sclerosing cholangitis.
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3-1) Inflammatory pseudotumour (IPT). IPT is an
entity that re-groups non-malignant lesions of the
extrahepatic bile duct with inflammatory compo-
nents. Histopathology findings are non-specific in-
flammation, fibrosis, cholangitis and granulomatosis
[413]. Aetiology remains unknown and the exact
incidence of this disease is difficult to evaluate.
However, between 5% and 20% of bile duct strictures
are IPT, which represents almost all the benign
aetiologies [413]. Associations with phlebitis, Crohn
disease and sclerosing cholangitis have been described
[5559]. In the case of mimicking tumours of
common bile duct, IPT occurs at 50 years, i.e. 10
years younger than CC occurs [9]. It develops near
extrahepatic bile duct and gallbladder. CA19-9 can be
normal or slightly elevated [38]. Radiological findings
cannot accurately distinguish benign from malignant
strictures. Indeed, 30% to 75% of IPTs show tumoral
syndrome on abdominal CT or MRCP even though
vascular invasion and/or encasement has never been
described in IPT [69,12,14]. Moreover, at least one
half of tumours seem to be maligns at laparotomy
[6,7,14]. That’s why Hadjis first called them ‘‘malig-
nant masquerade’’ [8].
3-2) Autoimmune pancreatocholangitis (lymphoplas-
macytic pancreatitis with cholangitis) (Figure 3). 
Autoimmune pancreatocholangitis (AIP) is character-
ized by lymphoplasmacytic cellular infiltrates that may
cause sclerosing inflammation of the biliary tree or
pancreatic duct [6062]. Patients present with ob-
structive jaundice. Imaging shows an inflammatory
mass of the lower part of the bile duct and the
pancreas, with enlargement of the gland [38,63]. The
strictures may be long and multiple and often mimic
PSC [62]. Serum IgG4 value 100 mg/ml is helpful
in distinguishing AIP from malignancy [61]. In
suspected cases, initial treatment with corticosteroid
can be proposed [64].
3-3) AIDS cholangiopathy (Figure 4).  First de-
scribed by Margulis in 1986, this event has become
rare since the introduction of antiviral therapy [65].
Patients are generally in advanced stages of their
disease [66]. At MRCP or cholangiography, the entire
biliary tree can be affected, but papillary stenosis with
or without dilatation of the main pancreatic duct is
unique in AIDS cholangiopathy and establishes the
diagnosis [66].
3-4) Other cholangitis.  Ischaemic cholangitis,
recurrent pyogenic cholangitis and mast cell cholan-
giopathy can result in biochemical and radiological
findings such as PSC [66]. However, these aetiologies
are rare, and clinical presentation often suggests non-
malignant disease.
4) Portal biliopathy (Figure 5).  Patients presenting
with bile duct stricture and portal cavernoma are
usually suspected of having malignant disease. How-
ever, cavernoma can cause biliary obstruction. The
mechanism is either compression by venous dilatation
or ischaemia by cavernoma thrombosis [6769].
Extrahepatic portal vein thrombosis is the most
common cause of portal biliopathy, but cirrhosis,
portal vein fibrosis without cirrhosis and congenital
hepatic fibrosis have been reported, too [70]. Most
patients have no symptoms [7173]. Direct cholan-
giographic findings, including segmental upstream
dilatation, calibre irregularity, stricture and extrinsic
impression on the bile duct due to collaterals, have
been called ‘‘pseudocholangiocarcinoma signs’’ [71].
However, transabdominal sonography or endoscopic
sonography can reveal venous collaterals within or
surrounding the extrahepatic bile duct [74]. Portal
MR and MRCP show paracholedochal and/or epi-
choledochal dilatations, and identify portosystemic
shunts and morphology of the bile duct [69,71].
Treatment by portosystemic shunt surgery allows
regression of biliopathy only when the mechanism is
compression [69].
5) Adenoma and papilloma of the bile duct (Figure 6).
 This is a rare benign epithelial tumour, with only
100 cases reported in the literature [75]. The mean
age of diagnosis of adenoma of the bile duct is 58
years, with a slight female predominance [76]. The
radiographic features are often difficult to distinguish
from cholangiocarcinoma, particularly in the intra-
ductal growing type [77]. Most of these lesions
predominate in common bile duct, especially in distal
common duct and ampulla of Vater [7880]. USFigure 3. MRCP of autoimmune pancreatocholangitis.
Figure 4. MRCP of AIDS cholangiopathy.
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indicates non-shadowing intraluminal mass, some-
times with a pedicle [81]. Endoscopic sonography of
the bile ducts and cholangiography show complete or
incomplete obstruction of the bile ducts by an
endoluminal mass [80]. Treatment of this lesion is
surgery. Diagnostic may be suspected intraoperatively
if the tumour appears polypoid and moveable within
the bile duct. Then simple local resection is sufficient.
Finally, ECC is difficult to differentiate from other
aetiologies (benign or malignant). These findings
suggest aggressive surgical therapy in front of sus-
pected malignant stricture of the bile duct. Biopsy is
not mandatory because of lack of sensibility and cost-
effectiveness. However, we believe that a good knowl-
edge of the literature and accurate semiological
analysis can lead to diagnosis in most cases. In our
experience, this approach has resulted in a dramatic
decrease of mimicking tumours less than 10% (per-
sonal data). We believe that the dogma ‘‘accurate
differentiation of benign and malignant hilar lesions is
currently not possible outside the operating room, so
resection remains the most reliable way to rule out
biliary malignancy’’ has to be considered with great
care and circumspection [9].
Intrahepatic cholangiocarcinoma (ICC)
ICC is a biliary tumour developed within the liver.
The incidence is tending to rise throughout the world
and, in all age groups, both genders, median size as
well as tumour stage remain unchanged, suggesting a
real increase rather than improvement in detection
rate [3]. Risk factors of ICC are PSC, hepatolithiasis,
parasitic infections, chemical carcinogen exposure
and viral hepatitis [3]. Symptoms as well as biochem-
ical investigation are often non-specific [1]. Curative
treatment consists in partial liver resection with lymph
node dissection. Factors of poor prognosis are infil-
trative type of ICC with satellite nodules and positive
lymph nodes.
ICC develops in normal liver. Classically, in the
mass-forming type it appears as a hypovascular
tumour with fibrotic component that can induce
portal compression [82]. Capsular retraction and
localized dilatation of peritumoral bile ducts are
frequent. ICC is often associated with lymph node
metastases.
ICC can be confused with fibrous metastases of
carcinomas such as breast cancer and colorectal
cancer [82]. These tumours develop within normal
liver like ICC, with similar age of incidence. Absence
of the possible primary site, a relatively large tumour
size and ancillary findings such as bile duct dilatation
can be clues in differentiating mass-forming cholan-
giocarcinomas from metastases. If not, we advocate
two approaches: 1) Biopsy of the lesion has not yet
been performed: clinical examination, colonoscopy
and mammography are useful, first to eliminate a
primary related to liver metastases, and second
because patients of 50 years of age or more are
usually candidates for screening for these two diseases
[83]. If these examinations are negative, we retain the
diagnosis of ICC and perform liver resection with
lymph node dissection. 2) Biopsy has been realized
Figure 5. CPRE and MRCP of portal biliopathy.
Figure 6. ERCP of bile duct adenoma.
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but is non-conclusive: the lesion is a metastasis of
adenocarcinoma from unknown primary (ACUP).
Thirty per cent of metastases from ACUP are within
the liver [84]. Prognosis is very poor, with a median
survival between 6 and 12 months [8587]. Even
chemotherapy cannot improve survival significantly
[85,87,88]. Surgery has never been evaluated in
ACUP because of often advanced disease with me-
tastases at other sites. However, when resections have
been made, no further study has found a poorer
prognosis than chemotherapy [87,89,90]. Therefore,
in the case of a unique lesion with no extrahepatic
disease, we advocate local resection with lymph node
dissection because: (a) survival is not different from
chemotherapy [89], (b) postoperative morbidity is low
in liver resections, (c) histological and molecular
analysis of the entire lesion can lead to the final
diagnosis and permits accurate adjuvant therapy [91],
and (d) in case atypical ICC treatment is complete.
In our opinion, ACUP has become a rare event.
The incidence of ICC has been increasing for several
decades, whereas the incidence of ACUP has been
decreasing simultaneously. Some authors have postu-
lated that a rise in incidence rate of ICC is a true
increase because there are no significant changes in
the staging and size of tumour at diagnosis [2].
However, the reason for this increase remains un-
known [92]. We therefore believe that many ACUPs
in past decades were ICC misdiagnosed. The rise in
incidence of ICC is in fact due to improvement of
diagnostic tools that help towards the correct diag-
nosis in most cases.
For this reason, all intrahepatic fibrous tumours
with no evidence of primary tumour site must be
considered as ICC. Biopsy is not mandatory, and
surgical therapy with segmental liver resection and
lymph node dissection must be performed.
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